Andere Sprachen Aptose Biosciences Inc.

Aktien

A3EENM

CA03835T3091

APS

Verzögert Toronto S.E. Andere Börsenplätze 19:21:39 30.04.2024			% 5 Tage	% 1. Jan.
1.69 ^CAD	+2.42%		+2.42%	-49.55%

26.03.	Aptose Biosciences Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI
26.03.	Transcript : Aptose Biosciences Inc., Q4 2023 Earnings Call, Mar 26, 2024

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

APTE BIOS : Material Agreement - Form 8-K	26.04.
Certain Warrants of Aptose Biosciences Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2024.	25.04.
Certain Common Shares of Aptose Biosciences Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2024.	25.04.
APTE BIOS : Aptose Corporate Presentation April 2024	24.04.
Aptose Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26.03.
Aptose Biosciences Up 3% After Hours as its 2023 Loss Widens on Higher R&D Spending	26.03.
Aptose Biosciences Brief: Says Luxeptinib G3 Formulation Achieved "Desired Levels and Positions for Future Trials"	26.03.
Aptose Biosciences Brief: Says Tuspetinib to Advance to TUS+VEN+HMA Triplet Therapy Pilot Study in 1L AML; Adds Tuspetinib "Continues Broad Activity Across Mutations with Excellent Safety Profile"	26.03.
Aptose Biosciences Brief: Q4 Basic and diluted loss per Common Share US$7.58	26.03.
Aptose Reports Results for the Fourth Quarter and Full Year 2023	26.03.
Aptose Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26.03.
North American Morning Briefing : Markets Steady -2-	26.03.
North American Morning Briefing : Stock Futures -2-	19.03.
Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024	18.03.
Top Premarket Gainers	02.02.
Aptose Biosciences Down 3% After Hours as it Raises US$13.7 Million in a Bought-Deal Offering, Private Placement	31.01.
Aptose Biosciences Raises US$13.7 Million in a Bought-Deal Offering of Share Units and Concurrent Private Placement	31.01.
Aptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option	31.01.
Aptose Biosciences Brief: Announcing Closing of US$9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option	31.01.
Aptose Biosciences Inc. announced that it has received $4 million in funding from Hanmi Pharm. Co., Ltd.	31.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Aptose Biosciences Inc.

Aktien

A3EENM

CA03835T3091

APS

Andere Sprachen

Filter